The CADTH Scientific Advice Program is a voluntary, fee-for-service consultation offered to pharmaceutical companies. Through this Program, CADTH offers advice on early drug development plans from a health technology assessment perspective.

The Scientific Advice Program enables pharmaceutical companies to receive guidance on what CADTH considers to be complete and relevant evidence for a future formulary review of their product by the CADTH Common Drug Review.

For CADTH, the Scientific Advice Program provides an opportunity to influence the evidence generated, potentially leading to more complete and relevant evidence on which to base CADTH recommendations. Stronger recommendations benefit Canadian decision-makers, who use the recommendations to create policies related to drug reimbursement; and Canadian patients, who are impacted by the policies put in place.

For more details, go to: https://scientificadvice.cadth.ca/en/